IPO Journey
Eloxx Pharmaceuticals, Inc.
IPO Date: June 9, 2026 · 4 filings tracked
Final Offer Terms
Ticker
ELOX
Exchange
Nasdaq Capital Market
Offer Price
$11.00
Shares Offered
2,975,000
Estimated Proceeds
$32.7M
Expected Listing
June 10, 2026
Underwriters
Led by Leerink Partners, Guggenheim Securities
LifeSci Capital
Filing Timeline
1
S-1
May 7, 2026
- Proprietary TURBO-ZM™ platform targets genetic 'typos' to restore protein production.
- Lead candidate ELX-02 is in clinical development for rare Alport syndrome.
2
S-1/A
June 1, 2026
- Innovative 'read-through' technology targeting rare genetic diseases
- Lead candidate exaluren focused on high-need Alport syndrome
Changes from previous filing
- ▸ Ticker symbol removed
3
S-1/A
June 4, 2026
- Developing innovative 'spell-check' genetic therapy for rare diseases
- Lead drug candidate ELX-02 targeting Alport syndrome
424B4
Final Pricing
June 9, 2026
- Proprietary TURBO-ZM™ platform enables genetic 'spell-checking' to treat rare diseases.
- Lead drug candidate ELX-02 is currently targeting rare kidney conditions like Alport syndrome.
Changes from previous filing
- ▸ Ticker symbol: ELOX
- ▸ Exchange: Nasdaq Capital Market
- ▸ Final offer price: $11.0 per share
- ▸ Shares offered: 2,975,000
- ▸ Estimated proceeds: $32M
- ▸ Underwriters: Leerink Partners, Guggenheim Securities, LifeSci Capital
Disclaimer: AI-generated analysis for informational purposes only. Not financial advice. Always conduct your own research.